A carregar...

A recombinant single chain antibody interleukin-2 fusion protein.

Recombinant interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell carcinoma. However its use can be limited by severe systemic toxicity. Targeting rIL-2 to the tumour should improve the anti-tumour immune response and decrease the syste...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Savage, P., So, A., Spooner, R. A., Epenetos, A. A.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1993
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1968162/
https://ncbi.nlm.nih.gov/pubmed/8431359
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!